TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
← catalyst calendarNCT07052903 · readout in 1,378 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,750estimated
Sites
251
Countries
Argentina, Australia, Austria +32
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-02 | actual | When the study began enrolling |
| Primary completion | 2030-05-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin Amyloidosis With Cardiomyopathy
Interventions
- Drug: Nucresiran — also filed as ALN-TTRSC04
- Drug: Sterile Normal Saline (0.9% NaCl)
Primary outcome
what the primary-completion date above is the date OFComposite outcome of all-cause mortality and recurrent cardiovascular [CV] events (CV hospitalizations and urgent heart failure [HF] visits)
measured Baseline to end of double-blind period (estimated 32 months, maximum 5 years)
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed